Under the name of Frontotemporal Dementias (FTD) numerous hereditary and sporadic disorders are listed. FTD may take away speech and language, social skills and ethical judgement, wishes and will, empathy and emotions; it may also impair motor functions. FTD may affect men and women in midlife or during old age leading to the demolition of the uniqueness of the human mind. In the last decade of the 20th century and in the first two decades of the 21st century, progress in the understanding of clinical, neuropathological, biochemical, and genetic aspects of FTD has accelerated. The novel awareness about FTD has directed young generations of researchers toward the study of this complex group of disorders. This Volume has been formulated with the participation of some of the leading scientists who have contributed to the development of knowledge in the clinical and basic science arenas. It captures the current central elements that are relevant to an up-to-date understanding of causes and pathogenesis of multiple forms of FTD. The volume is an opus that represents a distillation of the work of many scientists and addresses the current directions in the study of one of the most complex groups of diseases. In view of its structure, the book could also be used as a textbook, that offers both a broad and deep analysis of major areas in FTD. This book, planned by the International Society for Frontotemporal Dementias, is distinctive as it opens a window to a wide landscape about the biology of FTD. Thus, the book represents a moment of reflection on the present state of our knowledge of FTD and a collective vision toward scientific progress. The authors of each chapter share their knowledge and vision aimed at reducing the suffering which is caused by FTD.

Frontotemporal dementia (FTD) is a cruel disease, robbing patients of core human characteristics and wreaking havoc with relationships. Clinical and scientific interest in FTD and related disorders continues to grow rapidly, with major advances having occurred since this book's last publication. New clinical diagnostic criteria were published in 2011; new pathological discoveries have led to new diagnostic criteria; and major genetic discoveries have been made. This new edition covers these developments, providing the leading resource on FTD, PPA, PSP, CBD, FTD-ALS, and related disorders, now written by a more internationally representative group of authors than before. Providing an in-depth and expert synthesis of the status of our knowledge of FTD and related syndromes, the content includes chapters reviewing clinical, neuropsychiatric, neuropsychological, imaging, and other features of FTD and multidisciplinary approaches to patient management. Essential reading for specialist and generalist neurologists, psychiatrists, geriatricians, neuropsychologists, neuropathologists, and basic scientists in relevant fields.

PET and SPECT in Neurology highlight the combined expertise of renowned authors whose dedication to the investigation of neurological disorders through nuclear medicine technology has achieved international recognition. Classical neurodegenerative disorders are discussed as well as cerebrovascular disorders, brain tumors, epilepsy, head trauma, coma, sleeping disorders and inflammatory and infectious diseases of the CNS. The latest results in nuclear brain imaging are detailed. Most chapters are written jointly by a clinical neurologist and a nuclear medicine specialist to ensure a multidisciplinary approach. This state-of-the-art compendium will be valuable not only to neurologists and radiologists/nuclear medicine specialists but also to interested general practitioners and geriatricians. It is the second volume of a trilogy on PET and SPECT imaging in the neurosciences, the other volumes covering PET and SPECT in psychiatry and in neurobiological systems.

This book summarizes the advances in our understanding of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), as well as the potential relationship between the two.

Distils the most valuable discoveries in dementia research into clear, insightful chapters written by international experts.

Primary Progressive Aphasia and Other Frontotemporal Dementias: Diagnosis and Treatment of Associated Communication Disorders is the second volume in the “Medical Speech-Language Pathology” book series. It is intended to fill an unmet need to assist clinicians, students, and related healthcare professionals in the diagnosis and treatment of the title disorders. There is a growing population of individuals diagnosed with various forms of Frontotemporal Dementia (FTD) and Primary Progressive Aphasia (PPA), and this number is likely to increase as medical practitioners and speech-language pathologists (SLPs) become more expert at identifying these conditions. More clinicians will be seeing, and treating, patients with a diagnosis of FTD or PPA. Toward that end, the goal of this book is to expand this clinical knowledge base and support the development of skills in diagnosis, but also in clinical management. Within each chapter is a concise presentation of available evidence-based practice and research findings, with a focus on sharing information that is clinically applicable and digestible for non-researchers. Each chapter provides a comprehensive outline of testing that will assist in the diagnosis of the cognitive-communication disorders associated with FTD, PPAs, and primary progressive apraxia of speech (PPAOS). Disclaimer: Please note that ancillary content (such as documents, audio, and video, etc.) may not be included as published in the original print version of this book.

Frontotemporal Dementia is a comprehensive exploration of one of the most common but least recognized causes of dementia. This book provides unique access to the clinical and basic biological features of this important set of disorders.

Dr Daniel Gibbs is one of 50 million people worldwide with an Alzheimer's disease diagnosis. Unlike most patients with Alzheimer's, however, Dr Gibbs worked as a neurologist for twenty-five years, caring for patients with the very disease now affecting him. Also unusual is that Dr Gibbs had begun to suspect he had Alzheimer's several years before any official diagnosis could be made. Forewarned by genetic testing showing he carried alleles that increased the risk of developing the disease, he noticed symptoms of mild cognitive impairment long before any tests would have alerted him. In this highly personal account, Dr Gibbs documents the effect his diagnosis has had on his life and explains his advocacy for improving early recognition of Alzheimer's. Weaving clinical knowledge from decades caring for dementia patients with his personal experience of the disease, this is an optimistic tale of one man's journey with early-stage Alzheimer's disease. Soon to be a documentary film on MTV/Paramount +.

Completely rewritten and updated, this new edition is almost twice the size of its predecessor. Illustrated in colour throughout, and with contributions from the world's leading authorities, it is the definitive reference on the neuropathology of dementia. It gives practical guidance to pathologists, describes the contribution of neuroimaging to diagnosis, and surveys the clinical features of dementia. New material includes: Three entirely new chapters on neuroimaging, molecular diagnostics, and transgenic models. Two chapters on tauopathies under new authorship. A chapter under new authorship on synucleinopathies, which includes multiple system atrophy.

Psychopharmacology of Neurologic Disease, Volume 165 in the Handbook of Clinical Neurology series, provides clinicians with an up-to-date, critical review of the best approaches to treatment of neurologic disease as discussed by experienced clinical investigators. The book is organized into sections on dementia, delirium, movement disorders, hereditary degenerative disease, epilepsy and psychogenic seizures, brain vascular disease, pseudobulbar affect, traumatic brain injury, neuro-oncology, multiple sclerosis and other demyelinating disorders, chronic fatigue syndrome/fibromyalgia, pain, headache, sleep disorders, autoimmune encephalitis/anti- NMDA encephalitis, functional sensory neurologic symptom disorders and neurodevelopmental disorders. Each of these diagnostic categories has a significant incidence of behavioral symptomatology that is secondary to the neurologic diagnosis that can serve to complicate other therapeutic interventions, alter the course of illness, and cause distress in patients and family caregivers.